Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Active not recruiting 2Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1CNS 1

Conditions

Glioblastoma 1Endometrial Adenocarcinoma 1Advanced Cancer 1

Interventions

pembrolizumab 1251Specimen Handling 867Carboplatin 816Magnetic Resonance Spectroscopy 803Cyclophosphamide 794Cisplatin 715Nivolumab 646Paclitaxel 623Radiotherapy 564Gemcitabine 562Biopsy 529Bevacizumab 468Dexamethasone 433fludarabine 404Docetaxel 370venetoclax 365Oxaliplatin 362Fluorouracil 352Capecitabine 350atezolizumab 341Rituximab 326durvalumab 326Doxorubicin 313Radiosurgery 305Pemetrexed 302Drug Therapy 294Standard of Care 292Ipilimumab 289Etoposide 279Radiation 277

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × linrodostat × 1 year × Clear all
NCT03459222 2026-04-06

An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread

Bristol-Myers Squibb

Phase 1/2 Completed
229 enrolled 21 charts

Advanced Cancer

NCT04106414 2025-10-14

Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
24 enrolled
GynecologicSarcoma

Endometrial Adenocarcinoma

NCT04047706 2025-06-29

Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Northwestern University

Phase 1 Active not recruiting
18 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡